Care pathway, site of service, and what is already in the room — internal hemorrhoids office based treatment

1. Summary

The domain dossier's care-pathway section (§2) named itself "effectively unwritten" and flagged three specific holes: who performs the office procedure, whether treatment happens at the visit where it is diagnosed, and how the "two societies claim overlapping ownership" framing resolves. This pass closes the staffing question with a direct quote rather than an inference: a peer-reviewed AAFP summary of the 2024 ASCRS guideline states that rubber band ligation "is performed by surgeons or primary care physicians in-office" [9], and a Medicare local coverage determination separately authorizes nurse practitioners, physician assistants, and clinical nurse specialists to certify, order, and establish the plan of care for office infrared coagulation [5]. The two guideline bodies also disagree concretely, not just over "purview," on how mandatory pre-treatment anoscopy is. None of the three device clearances checked this pass names a site of service in its own indications for use — the office/facility distinction is a function of Medicare coverage policy and clinical practice, not FDA labeling. The only concrete visit-by-visit follow-up schedule located is a single non-US case series and does not establish a US pattern.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Who performs the procedure, and who refers

Two distinct authorities, addressing two distinct questions, both bear directly on the dossier's unresolved staffing gap. First, on physician specialty: a peer-reviewed AAFP summary of the 2024 ASCRS clinical practice guideline states plainly that office rubber band ligation "is performed by surgeons or primary care physicians in-office" [9] [single-source] — the guideline body most associated with colorectal surgery is, in this secondary summary, itself naming primary care as a legitimate performer of the procedure, which cuts against the dossier's framing of this as a two-specialty turf question. Second, on licensure within a practice: the Medicare local coverage determination for infrared coagulation states that "for outpatient settings other than a Comprehensive Outpatient Rehabilitation Facility (CORF), references to 'physicians' throughout this policy include nonphysicians, such as nurse practitioners, clinical nurse specialists and physician assistants. Such nonphysician practitioners, with certain exceptions, may certify, order and establish the plan of care as authorized by state law" [5] [single-source]. These are two different distinctions — which physician specialty, and which licensure level within a practice — and neither source addresses the other's question.

On referral out of the office pathway, three sources converge on the same substance: office-based procedures are used through grade III, with surgery reserved for grade IV or for grade III that fails banding. The AGA states "consultation with a surgeon should be offered to patients with grade 3 internal hemorrhoids who fail banding procedures... Grade 4 internal hemorrhoids require surgical hemorrhoidectomy" [4]. The Medicare LCD states "operative treatment is reserved for symptomatic patients with Grade III or IV hemorrhoids" [5]. An older AFP review adds a primary-care-specific referral trigger not present in either guideline: "patients who do not improve and those with large high-grade hemorrhoids should be referred for surgery" [2] [single-source] — a lower, symptom-based bar than "failed banding," suggesting family medicine's own referral threshold may trigger earlier than the specialty guidelines' failed-first-line-treatment standard.

The staged sequence, and where the guidelines actually disagree

All sources agree conservative management (fiber, fluids, topical agents, behavior change) precedes any procedure, and office banding/IRC/sclerotherapy precede surgery for grades I-III [1][4][5][9] — stated plainly, four independent non-affiliated sources. The Medicare LCD is more specific about dwell time than either clinical guideline: "at least 6 weeks may be required for significant improvement" from conservative therapy before medical necessity for a procedure is documented [5] [single-source].

Where the two guideline bodies genuinely diverge is initial evaluation, not just "purview." The AGA states anoscopy "should be performed, whenever possible, on every new patient with suspected hemorrhoids, prior to treatment, to ensure accurate diagnosis" [4] [single-source] — near-mandatory language. The AAFP's summary of the ASCRS guideline states only that "anoscopy can be considered to exclude other pathology" [9] [single-source] — permissive, not mandatory — while naming digital rectal exam, not anoscopy, as the thing that "is recommended." Both guidelines separately set a colonoscopy threshold: the ASCRS summary flags "no obvious source of bleeding or symptoms including abdominal pain, new or progressive constipation, and continued hematochezia despite successful treatment of hemorrhoids" as the trigger to look past hemorrhoids for colorectal cancer [9] [single-source].

Branch points that route around banding/IRC entirely

The AGA guideline names four situations where the office banding/IRC pathway is explicitly not the next step, none of which the dossier's §2 captured: acute thrombosed hemorrhoids, which are "best treated surgically with incision and drainage" rather than banded [4] [single-source] — consistent with a separate AFP review's statement that thrombosed external hemorrhoids should be excised "within the first two to three days of symptoms" [1] [single-source], two sources agreeing that acute thrombosis is a surgical, time-sensitive branch rather than an office-banding indication; active Crohn's disease or ulcerative colitis, where "hemorrhoid disease management should be delayed until complete remission is achieved" [4] [single-source]; significant coagulopathy (platelet count under 50,000/µL or INR over 2.0), where "infrared coagulation is preferred to banding" specifically because of bleeding risk [4] [single-source]; and pregnancy, where treatment is conservative first regardless of grade, with banding or IRC considered only "if symptoms persist postpartum, or if a woman is planning further pregnancies" [4] [single-source].

Site of service: a payment and practice-pattern construct, not an FDA one

Three cleared devices in this domain were checked directly against the phrase "office" in their own FDA indications for use, retrieved fresh this pass: the HET Bipolar Electrocautery Forceps and Monitor (K121085, decided 2012-11-20) is cleared for "grasping, manipulating and coagulating soft tissue during general surgery" and "the treatment of symptomatic Grade I and Grade II internal hemorrhoids," with no site-of-service language [6]; the Ultroid Hemorrhoid Management System (K030315, decided 2003-02-27) is cleared for "coagulative hemostatic therapy of internal hemorrhoids grades I, II, III, IV," also with no site-of-service language [7]; and the SleeveLUX Anoscope/Proctoscope (K250645, decided 2025-10-09) is cleared to "assist clinicians when treating and/or diagnose conditions in the anal canal and lower rectum," again without naming a site [8]. None of the three registry records this pass checked restricts or specifies where the device may be used [inference: see §5]. The actual basis for treating these procedures as office-appropriate comes from payer policy and clinical guidance instead: the Medicare LCD grounds coverage in Title XVIII §1861(s)(2), covering services and supplies "furnished as an incident to a physician's professional service, of kinds which are commonly furnished in physicians' offices" [5] [single-source], and the same LCD is a Palmetto GBA document applicable only to its own DME MAC Jurisdiction J states (Alabama, Georgia, Tennessee, South Carolina, Virginia, West Virginia, North Carolina) — a regional coverage instrument, not a national one, and this pass located no national coverage determination for hemorrhoid destruction procedures.

What one office series shows about visit cadence

One retrospective series of 890 outpatient rubber band ligation patients (2007-2013) gives the only concrete follow-up schedule located this pass: patients "were asked to return to outpatient clinic for follow-up at 2 weeks and 1 and 6 months and by telephone call every 6 months for 2 years" [3] [single-source], with "35 patients (4%) had some complications from RBL, which required no hospitalization" [3] [single-source]. The journal is Indian; the paper does not state a US setting, and this pass found no comparable US-population visit-cadence or office-safety series.

4. Sources

[1] Hemorrhoids: Diagnosis and Treatment Options — American Family Physician (published 2018-02-01; accessed 2026-09-01). PMID 29431977 — https://pubmed.ncbi.nlm.nih.gov/29431977/ [peer-reviewed] [2] Benign Anorectal Conditions: Evaluation and Management — American Family Physician (published 2020-01-01; accessed 2026-09-01). PMID 31894930 — https://pubmed.ncbi.nlm.nih.gov/31894930/ [peer-reviewed] [3] Rubber Band Ligation for Hemorrhoids: an Office Experience — The Indian Journal of Surgery (published 2016-08, day not given in the PubMed record; accessed 2026-09-01). PMID 27574343 — https://pubmed.ncbi.nlm.nih.gov/27574343/ [peer-reviewed] [4] AGA Clinical Practice Update on Diagnosis and Treatment of Hemorrhoids: Expert Review — Clinical Gastroenterology and Hepatology (published 2026, month not given in the PubMed record; accessed 2026-09-01). PMID 42067175 — https://pubmed.ncbi.nlm.nih.gov/42067175/ [peer-reviewed] [5] Infrared Coagulation (IRC) of Hemorrhoids, Local Coverage Determination — Centers for Medicare & Medicaid Services, contractor Palmetto GBA, DME MAC Jurisdiction J (revision effective 2023-07-06; accessed 2026-09-01 via the MCD Archive, document version 36, superseded — the current in-force version could not be rendered without JavaScript this pass). LCD 34422 (L34422) — https://localcoverage.cms.gov/mcd_archive/view/lcd.aspx?lcdInfo=34422:36 [payer-policy] [6] HET Bipolar Electrocautery Forceps and Monitor, 510(k) clearance summary — U.S. Food and Drug Administration (decided 2012-11-20; accessed 2026-09-01). K121085 — https://www.accessdata.fda.gov/cdrh_docs/pdf12/K121085.pdf [federal-registry] [7] Ultroid Hemorrhoid Management System, 510(k) clearance summary — U.S. Food and Drug Administration (decided 2003-02-27; accessed 2026-09-01). K030315 — https://www.accessdata.fda.gov/cdrh_docs/pdf3/K030315.pdf [federal-registry] [8] SleeveLUX 24/16 Anoscope/Proctoscope, 510(k) clearance summary — U.S. Food and Drug Administration (decided 2025-10-09; accessed 2026-09-01). K250645 — https://www.accessdata.fda.gov/cdrh_docs/pdf25/K250645.pdf [federal-registry] [9] Management of Hemorrhoids: Guidelines From the ASCRS — American Family Physician (published 2025-12, day not given in the journal record; accessed 2026-09-01). PMID 41533423 — https://www.aafp.org/pubs/afp/issues/2025/1200/practice-guidelines-hemorrhoids.html [guideline]

5. Sourcing & Gaps

Well established: conservative management before any procedure, and office-based banding/IRC/sclerotherapy before surgery for grade I-III disease, rests on four independent, non-affiliated sources [1][4][5][9] and is stated plainly. The grade III(-failed-banding)/grade IV surgical-referral threshold rests on two independent guideline-level sources agreeing in substance [4][5].

Thin: every staffing, dwell-time, branch-point, and follow-up-cadence claim in §3 rests on exactly one source and is marked [single-source] individually — this section could not corroborate most of its findings against a second, independent source. The Medicare site-of-service basis rests on one archived (superseded, version 36) LCD from one regional contractor covering seven states; no equivalent national coverage document was located, and the currently in-force version of the same LCD could not be retrieved (see below).

Rescoped from class 3: none in this report. Every proposition here is a registry fact (device clearances, the LCD's coding/coverage structure) or a published/guideline-stated finding; no question about what a clinician or patient would do was posed.

Out of scope: CPT descriptor text (AMA-licensed, never reproduced — only code-free prose is used here); MAUDE device-complaint narratives (no connector in this repo); any jurisdiction other than the US.

Not searched vs. not found: Not searched this pass — a second, non-Palmetto-GBA MAC's local coverage policy for IRC or RBL, which would test whether the grade-based coverage criteria and NP/PA/CNS authorization found in [5] are contractor-specific or effectively uniform nationally; any US-population study of visit-to-visit throughput or same-visit-vs-follow-up-visit treatment timing (the dossier's own §2 gap); the full ASCRS 2018/2024 guideline text itself, still paywalled per the domain dossier's prior attempt and not re-attempted this pass. Not found — a currently-in-force (non-archived) rendering of LCD L34422 reachable without a JavaScript-executing browser (attempted via direct fetch of both the versioned and unversioned URL; both returned either a redirect to the archived version or a JavaScript application shell with no static content); any US-based case series reporting an office visit-cadence or complication rate comparable to [3].

[inference] That the absence of site-of-service language in all three checked device clearances [6][7][8] means the office/facility distinction is entirely a payer-policy and practice-pattern construct rather than an FDA-labeled restriction is this report's own synthesis across three registry records, not a statement made by any single source.

6. Claim Candidates